DOCSLIB.ORG

Seasonal Allergies and Atopic Dermatitis: a Missing Link?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Seasonal Allergies and Atopic Dermatitis: a Missing Link? COVER FOCUS Seasonal Allergies and Atopic Dermatitis: A Missing Link? Evidence increasingly suggests that dermatologists need to watch for allergens in AD—from the interaction between environmental allergens and eczema to corticosteroid allergy. BY LEON H. KIRCIK, MD AND JAMES Q. DEL ROSSO, DO ommon seasonal allergy symptoms—itchy eyes, creating buzz not only about corticosteroids in general runny noses, and scratchy throats—lead many but also their cross-reactivity among themselves.3 Table patients to visit an allergist, but a growing num- 1 shows five core structural classes: A, B, C, D1, and D2. ber are seeking help at dermatologists’ offices as Cross-reactivity issues spark the need to screen patients Cwell. Allergen exposure through the skin may initiate sys- temic allergies especially, in patients who are predisposed TAKE HOME TIPS to atopic dermatitis (AD), allergic rhinitis, and asthma.1,2 While many dermatologists may be aware of this research, Allergen exposure through the skin may initiate systemic the implications for patient care may be less obvious. allergies especially, in patients who are predisposed to atopic Airborne allergens from pollen, trees, grass, plants, and dermatitis (AD), allergic rhinitis, and asthma. Airborne ragweed can cause these typical allergic reactions, and the allergens from pollen, trees, grass, plants, and ragweed can heightened systemic response to allergens may instigate a cause typical allergic reactions, and the heightened systemic flare of AD. Furthermore, contact allergy or other cutaneous response to allergens may instigate a flare of AD; contact reactions can also result when allergens comes into contact allergy or other cutaneous reactions can also result when with the skin. Reactions typically include pruritus, erythema- allergens comes into contact with the skin. When topical tous eruptions, and urticaria. When topical corticosteroids corticosteroids are used the issue of allergy may be com- are used to treat eczema or skin reactions associated with pounded. Although uncommon, some patients do develop seasonal allergies, the issue of allergy may be compounded. allergic contact dermatitis to topical corticosteroids used Although uncommon, some patients do develop allergic during treatment. Group C corticosteroids are associated contact dermatitis to topical corticosteroids used during with a lower risk of sensitization, relative to other classes, and treatment. In such cases, they may improve initially, how- may be preferred for long-term management of patients ever the eczematous eruption persists due to contact allergy with AD. In addition to prescription therapy, good skin care, to the active corticosteroid ingredient. incluidng barrier repair, is important. Finally, the role of vehi- cles and delivery systems in patient adherence as well as CORTICOSTEROID CLASSES repair of the disrupted epidermal barrier in chronic inflam- In 2005, the American Contact Dermatitis Society des- matory skin diseases is of utmost important. ignated corticosteroids their “allergen of the year,” thus 34 PRACTICAL DERMATOLOGY JUNE 2012 COVER FOCUS for class-specific sensitization through specified patch TIPS FOR PATIENTS tests, and studies have shown the possibility that some adverse drug reactions may be caused by cross-reactivity You may suggest the following to patients especially sensi- among different classes of corticosteroidsHeadline and sulfon- tive or allergic to seasonal pollens and grasses. amides.4-6 For example, Class A components can cross- react with Class D2, requiring caution for physicians to • Wear a mask and gloves when working outside, doing avoid prescribing a product in either class in a known household tasks, or grooming pets. sensitized patient.7-12 • Frequently launder clothing that has been worn for extend- Group C corticosteroids are associated with a lower risk ed periods during gardening or mowing the lawn. of sensitization, relative to other classes, and may be pre- • Wash hair, face, arms, and legs after performing outside ferred for long-term management of patients with atopic Deck tasks. dermatitis. Group C corticosteroids were rarely allergenic • Bathe pets frequently, as they bring pollen inside on their in sensitization studies.14-16 Within this group, clocortolone fur and trigger pollen allergies. BYLINE pivalate cream 0.1% (Cloderm Cream, Promius Pharma) offers a reasonable balance of safety and efficacy, and is and atopic dermatitis, their efficacy often is hindered by well suited to manage inflammatory dermatoses.13 Clinical patient non-adherence issues and the emergence of side studies have shown that clocortolone pivalate cream 0.1% effects.20-22 Much effort has gone into devising more effec- is a safe andext text effective text text treatment text text in text AD, text contact text textdermati text - tive strategies for addressing the dry skin conditions asso- tis, eczema,text and text psoriasis, text text andtext thistext producttext text demonstratestext text text ciated with various dermatologic disorders by providing no cross-allergenicitytext text text textwith text the textA, B, text or Dtext corticosteroid text text text additional moisture content to products.22 Studies show classes.17-19text text text text text text text text text text text patients prefer less greasy treatments options over oint- textT text text text text text text text text text text ment corticosteroid formulations.23,24 While there remains ADHERENCE STRATEGIES a role for ointments in patient care, they are best for acute Selecting an appropriate topical corticosteroid is just treatment for short term use. An emollient-type cream or a first step. While topical corticosteroids are the most aqueous-based gel is more likely to encourage long-term common treatment modality for patients with psoriasis adherence due to ease of use and spreadability, lack of TABLE 1: CLASSES OF CORTICOSTEROIDS1 Class A — Hydrocortisone Type Hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, prednisolone, methylprednisolone, cloprednol, fludro- cortisone, and prednisone Class B — Acetonides (and related substances) Triamcinolone acetonide, triamcinolone alcohol, mometasone, amcinonide, budesonide, desonide, fluocinonide, fluocinolone aceton- ide, flunisolide, procinonide, and halcinonide Class C — Betamethasone Type Betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium phosphate, desoximetasone, clocorto- lone pivalate, rimexolon, and flucortolone Class D — Esters Class D1 — Less Labile Clobetasol propionate, hydrocortisone-17-valerate, aclometasone dipropionate, betamethasone valerate, betamethasone dipropio- nate, prednicarbate, clobetasone-17-butyrate, clobetasol-17-propionate, fluocortolone caproate, fluocortolone pivalate, and flupred- nidene acetate Class D2 — Labile Prodrug Esters Hydrocortisone-17-butyrate, 17-aceponate, 17-buteprate, and prednicarbate 1. Rietschel RL, Fowler JF, Fisher AA. Fisher’s Contact Dermatitis. Lewiston, New York: BC Decker; 2008; 257. JUNE 2012 PRACTICAL DERMATOLOGY 35 COVER FOCUS Leon H. Kircik, MD, FAAD is Director of Derm Good overall skincare, including use Research, PLLC and Physicians Skin Care, PLLC. of moisturizing barrier repair creams, He is Clinical Associate Professor of Dermatology at Mount Sinai Medical Center and Indiana may be helpful for these patients, University School of Medicine. especially if they are attentive to James Q. Del Rosso, DO, FAOCD is Dermatology Residency barrier management in advance of Program Director at Valley Hospital Medical Center in Las Vegas, Nevada; Clinical Professor (Dermatology) at Touro allergy season. University College of Osteopathic Medicine in Henderson, Nevada; and in private practice at Las Vegas Skin & Cancer messiness and residue caused by the vehicle, and lack of Clinics, Las Vegas and Henderson, Nevada. skin irritation. Another key factor in patient adherence is the amount of 1. Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010; 105(2):99-106. 2. Morgenstern V, Zutavern A, Cyrys J, et al. Atopic diseases, allergic sensitization, and exposure to traffic-related air drug prescribed and the method of dispensing it. Especially pollution in children. Am J Respir Crit Care Med. 2008; 177(12):1331-7. for management of recurrent or chronic dermatoses, pre- 3. American Contact Dermatitis Society. History of allergen of the year. http://www.contactderm.org/i4a/pages/index. cfm?pageid=3467 scribers should be sure to order a sufficient quantity of 4. Rerkpattanapipat T, Chiriac AM, Demoly P. Drug provocation tests in hypersensitivity drug reactions. Curr Opin Allergy medication to meet the patient’s need between office visits. Clin Immunol. 2011; 11(4):299-304. 5. Patel JS, Scheiner ED. Acute parotitis induced by trimethoprim/sulfamethoxazole. Ear Nose Throat J. 2011; 90(2):E22. More recently, metered pumps have come on the market, 6. Baxter JD, Funder JW, Apriletti JW, et al. Towards selectively modulating mineralocorticoid receptor function: lessons helping patients to more accurately “dose” their topical from other systems. Mol Cell Endocrinol. 2004; 217(1-2):151-65. 7. Jacob SE, Steele T. Corticosteroid classes: a quick reference. J Am Acad Dermatol. 2006; 54:723-7. medications and not overuse them. Metered-pumps are 8. De Groot AC, Weyland JW, Nater JP. Unwanted effects of cosmetics and drugs used in dermatology. Third Ed. associated with high rates of patient satisfaction. Amsterdam: Elsevier; 1994. 9.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Pre - PA Allowance Age 18 Years of Age Or Older Quantity 60 Grams Every 90 Days ______
    DOXEPIN CREAM 5% (Prudoxin, Zonalon) Pre - PA Allowance Age 18 years of age or older Quantity 60 grams every 90 days _______________________________________________________________ Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: Moderate pruritus, due to atopic dermatitis (eczema) or lichen simplex chronicus AND the following: 1. Inadequate response, intolerance or contraindication to ONE medication in EACH of the following categories: a. Topical antihistamine (see Appendix I) b. High potency topical corticosteroid (see Appendix II) 2. Physician agrees to taper patient’s dose to the FDA recommended dose, and after tapered will only use for short-term pruritus relief (up to 8 days) a. Patients using over 60 grams of topical doxepin in 90 days be required to taper to 60 grams topical doxepin within 90 days Prior - Approval Limits Quantity 180 grams for 90 days Duration 3 months ___________________________________________________________________ Prior – Approval Renewal Requirements None (see appendix below) Doxepin 5% cream FEP Clinical Rationale DOXEPIN CREAM 5% (Prudoxin, Zonalon) APPENDIX I Drug Dosage Form Diphenhydramine Cream Phenyltoloxamine Lotion/ Cream Tripelennamine Cream Phendiamine Cream APPENDIX II Relative Potency of Selected Topical Corticosteroid Drug ProductsDosage Form Strength I. Very high potency Augmented betamethasone Ointment, Gel 0.05% dipropionate Clobetasol propionate Cream, Ointment 0.05% Diflorasone diacetate Ointment 0.05% Halobetasol propionate Cream, Ointment 0.05% II. High potency Amcinonide Cream, Lotion, 0.1% Augmented betamethasone Cream,Ointment Lotion 0.05% dipropionate Betamethasone Cream, Ointment 0.05% Betamethasonedipropionate valerate Ointment 0.1% Desoximetasone Cream, Ointment 0.25% Gel 0.05% Diflorasone diacetate Cream, Ointment 0.05% (emollient base) Fluocinonide Cream, Ointment, Gel 0.05% Halcinonide Cream, Ointment 0.1% Triamcinolone acetonide Cream, Ointment 0.5% III.
    [Show full text]
  • Cloderm® Cream (Clocortolone Pivalate 0.1%): a Moisturizing, Hydrating Formulation Enhances Epidermal Barrier Function
    CLINICAL INSIGHTS SUPPORTED BY PROMIUS PHARMA 2013, No. 2 Cloderm® Cream (clocortolone pivalate 0.1%): A Moisturizing, Hydrating Formulation Enhances Epidermal Barrier Function Leon Kircik, MD, FAAD It has been shown that application of some topical corti- DermResearch, PLLC, costeroids can increase TEWL and potentially contribute to Physicians Skin Care, PLLC, epidermal barrier dysfunction.6,7 In mice, application of topical Indiana University Medical Center, Indianapolis, IN, corticosteroids induced progressive increases in TEWL and a Mount Sinai Medical Center, New York, NY reduction in intercellular lipids in the SC.7 It is now well known The stratum corneum (SC) is a dynamic structure marked that even short-term use of topical corticosteroids can com- by multiple complex interactions and feedback loops.1-4 Self- promise epidermal barrier function and SC integrity by inhibit- repair of the permeability barrier has been documented; i.e., the ing epidermal lipid synthesis.8 However, certain formulations of SC can quickly adapt and initiate natural physiologic recovery. topical corticosteroids have been shown to improve skin hydra- Dysfunction of the SC is associated with specific disease states, tion and reduce TEWL.9,10 Perhaps the beneficial or detrimental perhaps most notably atopic dermatitis (AD), but also rosacea, effects of a given topical corticosteroid on TEWL have less to do psoriasis, and other inflammatory cutaneous disorders. More with the corticosteroid itself than with the vehicle in which it precisely, researchers and clinicians believe that AD may be is delivered.11 Thus, treatment becomes an act of balancing the driven in part by poor epidermal barrier function, perhaps as negative effects of the corticosteroid molecule itself on epider- a result of impairments in the permeability, immune response, mal barrier versus the positive impact of the vehicle that deliv- and antimicrobial barriers.
    [Show full text]
  • Appendix 6 – Characteristics and Safety Data from the Included Studies
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Appendix 6 – Characteristics and safety data from the included studies How safe are topical corticosteroids compared to emollient or vehicle? Study ID Study design and Intervention and Participants Cutaneous adverse events Systemic adverse events Unspecified adverse events (Systematic study duration comparator review*) (Quality assessment) Very potent topical corticosteroids Breneman 2003 RCT Intervention: Clobetasol Severity: moderate Local application site skin Unspecified adverse events (1) propionate 0.05% lotion (twice a to severe reactions Incidence comparable between 2 weeks treatment, then day) (n=96) No clinically significant groups. (unpublished) followed up for Age: ≥ 12 years telangiectasia or skin thinning additional 2 weeks Intervention: Clobetasol Treatment-related adverse (Feldman 2005 Sample size: 229 propionate 0.05% emollient events (2) Nankervis (3)) Cochrane risk of bias tool: participants cream (twice a day) (n=100) Clobetasol lotion = 4/96 patients randomisation described, (4.2%); Clobetasol cream = 1/100 allocation concealment Comparator: Vehicle (n=33) patients (1%) unclear, intention-to- Vehicle = 6/33 patients (18.2%) treat unclear. (Difference between groups: p= 0.0006a) Kimball 2008 (4) RCT Intervention: Clobetasol Severity: not Incidence of adverse events or (trial a) propionate emulsion specified in the treatment related adverse Duration not specified in formulation foam 0.05% review events (Frangos 2008 review Clobetasol foam = 8% (5)) Comparator: Vehicle Age: not specified in Risk of bias not assessed Vehicle foam = 10% the review in any of the included (no significant differences systematic reviews.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0045488 A1 RODRGUEZ (43) Pub
    US 20080045488A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0045488 A1 RODRGUEZ (43) Pub. Date: Feb. 21, 2008 (54) PREVENTION OF OVARIAN CANCER BY Continuation-in-part of application No. 09/528,963, ADMINISTRATION OF PRODUCTS THAT filed on Mar. 21, 2000, now Pat. No. 6,765,002. INDUCE BIOLOGICAL EFFECTS IN THE Continuation-in-part of application No. 09/672,735, OVARIAN EPTHELIUM filed on Sep. 28, 2000, now Pat. No. 6.511,970. Continuation-in-part of application No. 09/532,340, (75) Inventor: Gustavo C. RODRIGUEZ, Durham, filed on Mar. 21, 2000, now abandoned. NC (US) Publication Classification Correspondence Address: JENNER & BLOCK, LLP (51) Int. Cl. ONE IBM PLAZA A6II 3/56 (2006.01) A 6LX 3/57 (2006.01) CHICAGO, IL 60611 (US) A6IP 35/00 (2006.01) (73) Assignee: New Life Pharmaceuticals Inc., Chi (52) U.S. Cl. ............................................ 514/171; 514/178 cago, IL (US) (57) ABSTRACT The present invention relates to compositions and methods (21) Appl. No.: 11/771,473 for preventing the development of epithelial ovarian cancer (22) Filed: Jun. 29, 2007 by administering compounds in an amount capable of regu lating TGF-B expression in the ovarian epithelium and/or Related U.S. Application Data capable of optimally altering expression of other Surrogate biomarkers identified by microarray technology. HRT and (63) Continuation of application No. 09/798,453, filed on OCP regimens comprising such compositions and methods Mar. 2, 2001. are disclosed. US 2008/0045488 A1 Feb. 21, 2008 PREVENTION OF OVARAN CANCER BY have been thought to increase ovarian cancer risk, whereas ADMINISTRATION OF PRODUCTS THAT INDUCE Some factors that Suppress ovulation have been thought to BIOLOGICAL EFFECTS IN THE OVARAN decrease risk.
    [Show full text]
  • LGC Standards Pharmacopoeial Reference Standards 2014
    LL CTS INKSP RODUTO A L P ITH W WEBSHO LGC Standards Pharmacopoeial reference standards 2014 FOR STANDARDS WITH CofA SEE OUR CATALOGUE: PHARMACEUTICAL IMPURITIES AND PRIMARY REFERENCE STANDARDS LGC Quality – ISO Guide 34 • GMP/GLP • ISO 9001 • ISO/IEC 17025 • ISO/IEC 17043 Pharmaceutical impurities Code Product CAS No. CS Price Unit Adiphenine Hydrochloride O LGC Standards N O MM1172.00 Adiphenine Hydrochloride 50-42-0 A 250mg HCl Pharmaceutical impurities and Adrenaline Tartrate OH H OH O OH primary reference standardsMM0614.00 2014 N OH Adrenaline Tartrate 51-42-3 A 500mg OH OH O OH OH H MM0614.02 L-Adrenaline 51-43-4 A 500mg OH N OH Imp. C (EP) as Hydrochloride: 1-(3,4-Di- O H OH MM0614.13 hydroxyphenyl)-2-(methylamino)ethanone 62-13-5 A 100mg N HCl Hydrochloride (Adrenalone Hydrochloride) OH (1R)-1-(3,4-Dihydroxyphenyl)-2- OH O S O MM0614.01 methylaminoethanesulphonic Acid H 78995-75-2 A 100mg OH N (Adrenaline -Sulphonate) OH Alanine NH2 MM0566.00 Alanine 56-41-7 A 500mg OH O Imp. A (Pharmeuropa): (2 S)-2-Aminobutanedioic Acid O NH 2 MM0567.00 OH (Aspartic Acid) 56-84-8 A 500mg OH O Albendazole O H MM0382.00 Albendazole N O 54965-21-8 A 500mg N H S N Imp. A (EP): 5-(Propylsulphanyl)-1H- H MM0382.01 N 80983-36-4 A 100mg NH2 benzimidazol-2-amine S N O H Imp. B (EP): Methyl [5-Propylsulphinyl)- N O MM0382.02 N 54029-12-8 A 100mg H 1H-benzimidazol-2-yl]carbamate S N O O H Imp.
    [Show full text]
  • PA Drug Name Generic Name PA Summary Name Epaned Enalapril
    Prior Authorization Drug Criteria Cross Reference PA Drug Name Generic Name PA Summary Name Epaned enalapril ACE Inhibitors and Combinations Perindopril perindopril ACE Inhibitors and Combinations Prestalia perindopril/amlodipine ACE Inhibitors and Combinations Qbrelis lisinopril ACE Inhibitors and Combinations Trandolapril/Verapamil ER by Greenstone trandolapril/verapamil ER ACE Inhibitors and Combinations Acanya clindamycin/benzoyl peroxide Acne and Rosacea Agents, Topical Aczone dapsone Acne and Rosacea Agents, Topical Altreno, Avita, Tretinoin, Retin-A Micro tretinoin Acne and Rosacea Agents, Topical Azelex, Finacea azelaic acid Acne and Rosacea Agents, Topical Clindamycin, Clindacin, Evoclin clindamycin Acne and Rosacea Agents, Topical Clindamycin 1%/Benzoyl Peroxide 5%, Neuac clindamycin/benzoyl peroxide Acne and Rosacea Agents, Topical Kit, Onexton Differin, Adapalene adapalene Acne and Rosacea Agents, Topical Epiduo, Epidue Forte adalpalene/benzoyl peroxide Acne and Rosacea Agents, Topical Ery Pad, erythromycin pad erythromycin Acne and Rosacea Agents, Topical Erythromycin/Benzoyl Peroxide erythromycin/benzoyl peroxide Acne and Rosacea Agents, Topical Metrogel, Metronidazole, Noritate, Rosadan metronidazole Acne and Rosacea Agents, Topical Fabior, Tazorac tazarotene Acne and Rosacea Agents, Topical Soolantra ivermectin Acne and Rosacea Agents, Topical Ziana tretinoin/clindamycin Acne and Rosacea Agents, Topical BPO Cloths benzoyl peroxide Acne and Rosacea Agents, Topical BP 10-1%, Sulfacetamide Sodium/Sulfur, sodium sulfacetamide/sulfur
    [Show full text]
  • Pequot Health Care Steps Program* Updated Oct 2021 *Enrollment in Steps Program Varies on Health Plan Sponsor
    Pequot Health Care - Pequot Pharmacuetical Network (PRxN) Pequot Health Care Steps Program* Updated Oct 2021 *Enrollment in Steps program varies on health plan sponsor. Member benefits and client contract will prevail. If you have que stions or need further assistance after consulting this table, call our Pharmacy Benefits number or the number on the back of your insurance card. Providers call 888-779-6638 for Authorization Form. Program effective 1-2014; Updated 9-2015, 10-2015, 1-2016, 3-2016, 10-2016, 01-2017, 04-2017, 7-2017, 02-2018, 04-2018, 05-2018, 08-2018, 11-2018, 4-2019, 6-2019, 9-2019, 12-2019, 4-2020, 6-2020, 10-2020, 1-2021, 7-2021, 10-2021 THERAPEUTIC DRUGS INCLUDED IN PROGRAM PREREQUISITE DRUGS CATEGORY (TARGET DRUGS) ALLERGY Previous use of one of the following generics either alone or as a Antihistamine Clarinex, Clarinex-D, Semprex, Xyzal component of a combination product: fexofenadine, levocetirizine, loratadine or cetirizine Acular and Acular LS (brand), Acuvail, Alocril, Alomide, Bepreve, Cromlon (brand), Elestat (brand), Emadine, Lastacraft, Optivar azelastine, cromolyn sodium, epinastine, ketotifen (rx-only), ketorolac Eye Drops (brand), Patanol (brand), Pazeo (brand and generic 0.7%), Pataday 0.4% and 0.5%, olopatadine 0.1% (brand and generic 0.2%), Zerviate (brand) Allergy Reaction AuviQ EpiPen Inhaled Nasal Beconase AQ, Dymista, Flunisolide, Nasonex, Omnaris, Qnasl, Previous use of the following generic: fluticasone nasal inhaler Steroids Rhinocort Aqua, Xhance, Zetonna ANTI-INFECTIVE Adoxa, Avidoxy, Doyxyxline
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]